The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

Birgit Vogel; Monica Acevedo; Yolande Appelman; C. Noel Bairey Merz; Alaide Chieffo; Gemma A. Figtree; Mayra Guerrero; Vijay Kunadian; Carolyn S. P. Lam; Angela H. E. M. Maas; Anastasia S. Mihailidou; Agnieszka Olszanecka; Jeanne E. Poole; Clara Saldarriaga; Jacqueline Saw; Liesl Zühlke; Roxana Mehran

doi:https://doi.org/10.1016/S0140-6736(21)00684-X

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

Birgit Vogel, Monica Acevedo, Yolande Appelman, C. Noel Bairey Merz, Alaide Chieffo, Gemma A. Figtree, Mayra Guerrero, Vijay Kunadian, Carolyn S. P. Lam, Angela H. E. M. Maas, Anastasia S. Mihailidou, Agnieszka Olszanecka, Jeanne E. Poole, Clara Saldarriaga, Jacqueline Saw, Liesl Zühlke, Roxana Mehran

Research output: Contribution to journal › Review article › Academic › peer-review

346 Citations (Scopus)

Abstract

Cardiovascular disease is the leading cause of death in women. Decades of grassroots campaigns have helped to raise awareness about the impact of cardiovascular disease in women, and positive changes affecting women and their health have gained momentum. Despite these efforts, there has been stagnation in the overall reduction of cardiovascular disease burden for women in the past decade. Cardiovascular disease in women remains understudied, under-recognised, underdiagnosed, and undertreated. This Commission summarises existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. Recommendations from an international team of experts and leaders in the field have been generated with a clear focus to reduce the global burden of cardiovascular disease in women by 2030. This Commission represents the first effort of its kind to connect stakeholders, to ignite global awareness of sex-related and gender-related disparities in cardiovascular disease, and to provide a springboard for future research.

Original language	English
Pages (from-to)	2385-2438
Number of pages	54
Journal	The Lancet
Volume	397
Issue number	10292
Early online date	2021
DOIs	https://doi.org/10.1016/S0140-6736(21)00684-X
Publication status	Published - 19 Jun 2021

Access to Document

https://doi.org/10.1016/S0140-6736(21)00684-X

Cite this

Vogel, B., Acevedo, M., Appelman, Y., Bairey Merz, C. N., Chieffo, A., Figtree, G. A., Guerrero, M., Kunadian, V., Lam, C. S. P., Maas, A. H. E. M., Mihailidou, A. S., Olszanecka, A., Poole, J. E., Saldarriaga, C., Saw, J., Zühlke, L., & Mehran, R. (2021). The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet, 397(10292), 2385-2438. Advance online publication. https://doi.org/10.1016/S0140-6736(21)00684-X

@article{60ad478685a14f84a1f8decb5fc4500b,

title = "The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030",

abstract = "Cardiovascular disease is the leading cause of death in women. Decades of grassroots campaigns have helped to raise awareness about the impact of cardiovascular disease in women, and positive changes affecting women and their health have gained momentum. Despite these efforts, there has been stagnation in the overall reduction of cardiovascular disease burden for women in the past decade. Cardiovascular disease in women remains understudied, under-recognised, underdiagnosed, and undertreated. This Commission summarises existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. Recommendations from an international team of experts and leaders in the field have been generated with a clear focus to reduce the global burden of cardiovascular disease in women by 2030. This Commission represents the first effort of its kind to connect stakeholders, to ignite global awareness of sex-related and gender-related disparities in cardiovascular disease, and to provide a springboard for future research.",

author = "Birgit Vogel and Monica Acevedo and Yolande Appelman and {Bairey Merz}, {C. Noel} and Alaide Chieffo and Figtree, {Gemma A.} and Mayra Guerrero and Vijay Kunadian and Lam, {Carolyn S. P.} and Maas, {Angela H. E. M.} and Mihailidou, {Anastasia S.} and Agnieszka Olszanecka and Poole, {Jeanne E.} and Clara Saldarriaga and Jacqueline Saw and Liesl Z{\"u}hlke and Roxana Mehran",

note = "Funding Information: MA reports personal fees from Bayer, Boehringer, Tecnofarma, and Axon, and non-financial support from Boehringer, outside the submitted work. YA reports grants from the Dutch Heart Foundation and has a patent image guided plaque ablation (USP 945593 licenced). CNBM reports grants from US National Institutes of Health (NIH) Study Section, Peer Review Medical Research Program Cardiovascular Health for the Department of Defense Congressionally Directed Medical Research Program, US National Heart, Lung, and Blood Institute (NHLBI) subcontract to Research Triangle Institute International, NHLBI R01, US National Institute on Aging U54, and Women's Ischemia Syndrome Evaluation HFpEF; consulting fees from the US Food and Drug Administration Renal Advisory Panel; and consulting fees or honoraria from iRhythm, Abbott Diagnostics, and Sanofi Vascular. AC reports personal fees from Abbott Vascular, Magenta, Biosensor, Abiomed, and Cardional Health. GAF reports grants from the Australian National Health and Medical Research Council and Abbott Diagnostics; and personal fees from CSL Behring and Janssen. VK reports personal fees from honoraria and for speaking from Bayer, Daichii Sankyo, Amgen, AstraZeneca, and Abbott, outside the submitted work. CSPL reports grants from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; personal fees from Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma, Us2.ai, JanaCare, Janssen Research & Development, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group, Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma, and WebMD Global; and has a patent pending (PCT/SG2016/050217), and a patent issued (16/216,929). JEP reports grants from BIOTRONIK and AtriCure. JS reports grants from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, Michael Smith Foundation of Health Research, and NIH; and consulting fees from Abbott Vascular, Boston Scientific, Gore, Baylis, and Abiomed. RM reports grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, Cerecor, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, OrbusNeich, and Zoll; personal fees from Boston Scientific, Cine-Med Research, Janssen Scientific Affairs, Medscape/WebMD, American College of Cardiology, and American Medical Association; non-financial support from Regeneron Pharmaceuticals; consultancy or advisory board fees paid to her institution from Abbott Laboratories, Beth Israel Deaconess, Bristol Myers Squibb, Chiesi, Concept Medical, Daiichi Sankyo, Medtronic, Novartis, CardiaWave, Duke University, Idorsia, Spectranetics/Philips/Volcano Corp; consultant fees paid to the institution of her spouse from Abiomed, Bayer; <1% equity in Applied Therapeutics, Elixir Medical, and STEL; and spouse's <1% equity in ControlRad. All other authors declare no competing interests. Funding Information: The Commission was supported financially by grants from Abbott Vascular, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, CSL Behring, Janssen, Medtronic, Orbus Neich, Philips, and Sanofi, who had no role in study design, data collection, data analysis, data interpretation, or writing of this Commission article. The funds were used towards the planning, development, and public launch of the Commission article. None of the authors were paid for their work on the Commission. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jun,

day = "19",

doi = "https://doi.org/10.1016/S0140-6736(21)00684-X",

language = "English",

volume = "397",

pages = "2385--2438",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10292",

}

Vogel, B, Acevedo, M, Appelman, Y, Bairey Merz, CN, Chieffo, A, Figtree, GA, Guerrero, M, Kunadian, V, Lam, CSP, Maas, AHEM, Mihailidou, AS, Olszanecka, A, Poole, JE, Saldarriaga, C, Saw, J, Zühlke, L & Mehran, R 2021, 'The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030', The Lancet, vol. 397, no. 10292, pp. 2385-2438. https://doi.org/10.1016/S0140-6736(21)00684-X

TY - JOUR

T1 - The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

AU - Vogel, Birgit

AU - Acevedo, Monica

AU - Appelman, Yolande

AU - Bairey Merz, C. Noel

AU - Chieffo, Alaide

AU - Figtree, Gemma A.

AU - Guerrero, Mayra

AU - Kunadian, Vijay

AU - Lam, Carolyn S. P.

AU - Maas, Angela H. E. M.

AU - Mihailidou, Anastasia S.

AU - Olszanecka, Agnieszka

AU - Poole, Jeanne E.

AU - Saldarriaga, Clara

AU - Saw, Jacqueline

AU - Zühlke, Liesl

AU - Mehran, Roxana

N1 - Funding Information: MA reports personal fees from Bayer, Boehringer, Tecnofarma, and Axon, and non-financial support from Boehringer, outside the submitted work. YA reports grants from the Dutch Heart Foundation and has a patent image guided plaque ablation (USP 945593 licenced). CNBM reports grants from US National Institutes of Health (NIH) Study Section, Peer Review Medical Research Program Cardiovascular Health for the Department of Defense Congressionally Directed Medical Research Program, US National Heart, Lung, and Blood Institute (NHLBI) subcontract to Research Triangle Institute International, NHLBI R01, US National Institute on Aging U54, and Women's Ischemia Syndrome Evaluation HFpEF; consulting fees from the US Food and Drug Administration Renal Advisory Panel; and consulting fees or honoraria from iRhythm, Abbott Diagnostics, and Sanofi Vascular. AC reports personal fees from Abbott Vascular, Magenta, Biosensor, Abiomed, and Cardional Health. GAF reports grants from the Australian National Health and Medical Research Council and Abbott Diagnostics; and personal fees from CSL Behring and Janssen. VK reports personal fees from honoraria and for speaking from Bayer, Daichii Sankyo, Amgen, AstraZeneca, and Abbott, outside the submitted work. CSPL reports grants from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; personal fees from Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma, Us2.ai, JanaCare, Janssen Research & Development, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group, Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma, and WebMD Global; and has a patent pending (PCT/SG2016/050217), and a patent issued (16/216,929). JEP reports grants from BIOTRONIK and AtriCure. JS reports grants from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, Michael Smith Foundation of Health Research, and NIH; and consulting fees from Abbott Vascular, Boston Scientific, Gore, Baylis, and Abiomed. RM reports grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, Cerecor, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, OrbusNeich, and Zoll; personal fees from Boston Scientific, Cine-Med Research, Janssen Scientific Affairs, Medscape/WebMD, American College of Cardiology, and American Medical Association; non-financial support from Regeneron Pharmaceuticals; consultancy or advisory board fees paid to her institution from Abbott Laboratories, Beth Israel Deaconess, Bristol Myers Squibb, Chiesi, Concept Medical, Daiichi Sankyo, Medtronic, Novartis, CardiaWave, Duke University, Idorsia, Spectranetics/Philips/Volcano Corp; consultant fees paid to the institution of her spouse from Abiomed, Bayer; <1% equity in Applied Therapeutics, Elixir Medical, and STEL; and spouse's <1% equity in ControlRad. All other authors declare no competing interests. Funding Information: The Commission was supported financially by grants from Abbott Vascular, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, CSL Behring, Janssen, Medtronic, Orbus Neich, Philips, and Sanofi, who had no role in study design, data collection, data analysis, data interpretation, or writing of this Commission article. The funds were used towards the planning, development, and public launch of the Commission article. None of the authors were paid for their work on the Commission. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/6/19

Y1 - 2021/6/19

N2 - Cardiovascular disease is the leading cause of death in women. Decades of grassroots campaigns have helped to raise awareness about the impact of cardiovascular disease in women, and positive changes affecting women and their health have gained momentum. Despite these efforts, there has been stagnation in the overall reduction of cardiovascular disease burden for women in the past decade. Cardiovascular disease in women remains understudied, under-recognised, underdiagnosed, and undertreated. This Commission summarises existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. Recommendations from an international team of experts and leaders in the field have been generated with a clear focus to reduce the global burden of cardiovascular disease in women by 2030. This Commission represents the first effort of its kind to connect stakeholders, to ignite global awareness of sex-related and gender-related disparities in cardiovascular disease, and to provide a springboard for future research.

AB - Cardiovascular disease is the leading cause of death in women. Decades of grassroots campaigns have helped to raise awareness about the impact of cardiovascular disease in women, and positive changes affecting women and their health have gained momentum. Despite these efforts, there has been stagnation in the overall reduction of cardiovascular disease burden for women in the past decade. Cardiovascular disease in women remains understudied, under-recognised, underdiagnosed, and undertreated. This Commission summarises existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. Recommendations from an international team of experts and leaders in the field have been generated with a clear focus to reduce the global burden of cardiovascular disease in women by 2030. This Commission represents the first effort of its kind to connect stakeholders, to ignite global awareness of sex-related and gender-related disparities in cardiovascular disease, and to provide a springboard for future research.

UR - http://www.scopus.com/inward/record.url?scp=85106556565&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0140-6736(21)00684-X

DO - https://doi.org/10.1016/S0140-6736(21)00684-X

M3 - Review article

C2 - 34010613

SN - 0140-6736

VL - 397

SP - 2385

EP - 2438

JO - The Lancet

JF - The Lancet

IS - 10292

ER -

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

Abstract

Access to Document

Other files and links

Cite this